Printer Friendly

AnGes MG Announces Results of Phase I Clinical Trial of HGF Gene Medicine.

Tokyo, Japan, May 11, 2006 - (JCN) - AnGes MG has announced the results of its phase I clinical trials of HGF (Hepatocyte Growth Factor) gene medicine conducted in the US.

In the trials, which covered nine serious cases, the company sought the availability of HGF gene medicine in the treatment of ischemic heart disease. The company says that no significant problem was confirmed in terms of initial safety up until three months after administration.

Currently, AnGes MG is proceeding research in the fields of peripheral vascular disease and ischemic heart disease. The company grants Daiichi Pharmaceutical rights to distribute the medicine in Japan, the US and Europe.

Copyright [c] 2006 Japan Corporate News Network. All rights reserved.
COPYRIGHT 2006 Japan Corporate News Network K.K.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2006, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Publication:JCNN News Summaries
Date:May 11, 2006
Previous Article:Eisai, Nitto Denko to Co-develop Transdermal Formulation of Alzheimer's Disease Agent ARICEPT.
Next Article:Roche Diagnostics to Make Its DNA Chip Available in Japan.

Related Articles
AnGes MG to Start Phase I Clinical Trial of NF-kappa B Decoy Oligodeoxynucleotide for Atopic Dermatitis.
AnGes MG, Avontec Enter into Cross Licensing Agreement for Decoy Nucleic Acid Drug.
AnGes MG Patents HVJ Envelope Vector in US.
AnGes MG Registers 9th Case of Phase I Clinical Trial for HGF Gene Medicine Conducted in US.
AnGes MG, FALCO biosystems to Form Business Alliance in Gene Therapy Business.
AnGes MG, Vical to Collaborate in Developing Genomic Drug for Skin Cancer.
AnGes MG Announces Results of Phase II Clinical Trials of HGF Gene Medicine.
AnGes MG Unveils Future Development Strategies for HGF Gene Medicine.
AnGes MG, Vical to Start Phase III Clinical Trial of Allovectin for Gene Therapy.

Terms of use | Privacy policy | Copyright © 2022 Farlex, Inc. | Feedback | For webmasters |